10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
BRISTOL MYERS SQUIBB CO | |||
Ticker: BMY Fiscal Year: 2009 | |||
Consolidated Statement Of Earnings | |||
Period Ending Dec 31, 2009 10-K (Filed: Feb 19, 2010) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2009 | Dec 31, 2008 | Dec 31, 2007 | |
| EARNINGS | |||
| Net Sales | $ 18,808 | 17,715 | 15,617 |
| Cost of products sold | 5,140 | 5,316 | 4,919 |
| Marketing, selling and administrative | 3,946 | 4,140 | 3,941 |
| Advertising and product promotion | 1,136 | 1,181 | 1,097 |
| Research and development | 3,647 | 3,512 | 3,160 |
| Acquired in-process research and development | 0 | 32 | 230 |
| Provision for restructuring | 136 | 215 | 180 |
| Litigation expense | 132 | 33 | 14 |
| Equity in net income of affiliates | (550) | (617) | (524) |
| Gain on sale of ImClone shares | 0 | (895) | 0 |
| Other (income)/expense | (381) | 22 | 77 |
| Total Expenses | 13,206 | 12,939 | 13,094 |
| Earnings from Continuing Operations Before Income Taxes | 5,602 | 4,776 | 2,523 |
| Provision for income taxes | 1,182 | 1,090 | 471 |
| Net Earnings from Continuing Operations | 4,420 | 3,686 | 2,052 |
| Discontinued Operations: | |||
| Earnings, net of taxes | 285 | 578 | 876 |
| Gain on disposal, net of taxes | 7,157 | 1,979 | 0 |
| Net Earnings from Discontinued Operations | 7,442 | 2,557 | 876 |
| Net Earnings | 11,862 | 6,243 | 2,928 |
| Net Earnings Attributable to Noncontrolling Interest | 1,250 | 996 | 763 |
| Net Earnings Attributable to Bristol-Myers Squibb Company | 10,612 | 5,247 | 2,165 |
| Amounts Attributable to Bristol-Myers Squibb Company: | |||
| Net Earnings from Continuing Operations | 3,239 | 2,697 | 1,296 |
| Net Earnings from Discontinued Operations | 7,373 | 2,550 | 869 |
| Net Earnings Attributable to Bristol-Myers Squibb Company | 10,612 | 5,247 | 2,165 |
| Earnings per Common Share from Continuing Operations Attributable to Bristol-Myers Squibb Company: | |||
| Basic | 1.63 | 1.36 | 0.65 |
| Diluted | 1.63 | 1.35 | 0.65 |
| Earnings per Common Share Attributable to Bristol-Myers Squibb Company: | |||
| Basic | 5.35 | 2.64 | 1.09 |
| Diluted | 5.34 | 2.62 | 1.09 |
| Dividends declared per common share | 1.25 | 1.24 | 1.15 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
BRISTOL MYERS SQUIBB CO | |||
Ticker: BMY Fiscal Year: 2009 | |||
Consolidated Statement Of Other Comprehensive Income | |||
Period Ending Dec 31, 2009 10-K (Filed: Feb 19, 2010) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2009 | Dec 31, 2008 | Dec 31, 2007 | |
| COMPREHENSIVE INCOME | |||
| Net earnings | $ 11,862 | 6,243 | 2,928 |
| Other Comprehensive Income/(Loss): | |||
| Foreign currency translation | 159 | (123) | 240 |
| Foreign currency translation reclassified to net earnings due to business divestitures | (40) | (12) | 0 |
| Foreign currency translation on hedge of a net investment | (38) | 36 | (141) |
| Derivatives qualifying as cash flow hedges, net of taxes of $9 in 2009, $(3) in 2008 and $24 in 2007 | (19) | 9 | (56) |
| Derivatives qualifying as cash flow hedges reclassified to net earnings, net of taxes of $5 in 2009, $(23) in 2008 and $(15) in 2007 | (27) | 42 | 42 |
| Derivatives reclassified to net earnings due to business divestitures, net of taxes of $(1) in 2009 | 2 | 0 | 0 |
| Pension and postretirement benefits, net of taxes of $41 in 2009, $697 in 2008 and $(52) in 2007 | (115) | (1,387) | 130 |
| Pension and postretirement benefits reclassified to net earnings, net of taxes of $(49) in 2009, $(50) in 2008 and $50 in 2007 | 109 | 102 | 108 |
| Pension and postretirement benefits reclassified to net earnings due to business divestitures, net of taxes of $(62) in 2009 | 106 | 0 | 0 |
| Available for sale securities, net of taxes of $(4) in 2009, $0 in 2008 and $19 in 2007 | 35 | (106) | (139) |
| Available for sale securities reclassified to net earnings, net of taxes of $(3) in 2009 and $(6) in 2008 | 6 | 181 | 0 |
| Total Other Comprehensive Income/(Loss) | 178 | (1,258) | 184 |
| Comprehensive Income | 12,040 | 4,985 | 3,112 |
| Comprehensive Income Attributable to Noncontrolling Interest | 1,260 | 996 | 763 |
| Comprehensive Income Attributable to Bristol-Myers Squibb Company | 10,780 | 3,989 | 2,349 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
BRISTOL MYERS SQUIBB CO | |||
Ticker: BMY Fiscal Year: 2009 | |||
Consolidated Statement Of Cash Flows | |||
Period Ending Dec 31, 2009 10-K (Filed: Feb 19, 2010) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2009 | Dec 31, 2008 | Dec 31, 2007 | |
| Cash Flows From Operating Activities: | |||
| Net earnings | $ 11,862 | 6,243 | 2,928 |
| Adjustments to reconcile net earnings to net cash provided by operating activities: | |||
| Net earnings attributable to noncontrolling interest | (1,250) | (996) | (763) |
| Depreciation | 469 | 562 | 542 |
| Amortization | 238 | 254 | 350 |
| Deferred income tax expense/(benefits) | 163 | 1,430 | (416) |
| Stock-based compensation expense | 183 | 181 | 133 |
| Acquired in-process research and development | 0 | 32 | 230 |
| Impairment charges | 0 | 349 | 379 |
| Gain related to divestitures of discontinued operations | (7,275) | (3,412) | 0 |
| Gain on sale of ImClone shares | 0 | (895) | 0 |
| Other (gains)/losses | (367) | (158) | (223) |
| Changes in operating assets and liabilities: | |||
| Receivables | 227 | (360) | (458) |
| Inventories | 82 | 130 | (54) |
| Accounts payable | 472 | 253 | 141 |
| Deferred income | 135 | 61 | 454 |
| U.S. and foreign income taxes payable | 58 | 371 | (199) |
| Changes in other operating assets and liabilities | (932) | (338) | 109 |
| Net Cash Provided by Operating Activities | 4,065 | 3,707 | 3,153 |
| Cash Flows From Investing Activities: | |||
| Proceeds from sale of marketable securities | 2,075 | 560 | 20,634 |
| Purchases of marketable securities | (3,489) | (422) | (19,878) |
| Additions to property, plant and equipment and capitalized software | (730) | (941) | (843) |
| Proceeds from sale of businesses, property, plant and equipment and other investments | 557 | 309 | 317 |
| Proceeds from divestitures of discontinued operations | 0 | 4,530 | 0 |
| Mead Johnson's cash at split-off | (561) | 0 | 0 |
| Purchase of businesses, net of cash acquired | (2,232) | (191) | (432) |
| Proceeds from sale of ImClone shares | 0 | 1,007 | 0 |
| Proceeds from sale and leaseback of properties | 0 | 227 | 0 |
| Net Cash (Used in)/Provided by Investing Activities | (4,380) | 5,079 | (202) |
| Cash Flows From Financing Activities: | |||
| Short-term debt repayments | (26) | (1,688) | (33) |
| Long-term debt borrowings | 1,683 | 1,580 | 0 |
| Long-term debt repayments | (212) | (229) | (1,300) |
| Interest rate swap terminations | 194 | 211 | 0 |
| Issuances of common stock under stock plans and excess tax benefits from share-based payment arrangements | 45 | 5 | 333 |
| Dividends paid | (2,483) | (2,461) | (2,213) |
| Proceeds from Mead Johnson initial public offering | 782 | 0 | 0 |
| Net Cash Used in Financing Activities | (17) | (2,582) | (3,213) |
| Effect of Exchange Rates on Cash and Cash Equivalents | 39 | (29) | 45 |
| (Decrease)/Increase in Cash and Cash Equivalents | (293) | 6,175 | (217) |
| Cash and Cash Equivalents at Beginning of Year | 7,976 | 1,801 | |
| Cash and Cash Equivalents at End of Year | 7,683 | 7,976 | 1,801 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
BRISTOL MYERS SQUIBB CO | ||
Ticker: BMY Fiscal Year: 2009 | ||
Consolidated Balance Sheets | ||
Period Ending Dec 31, 2009 10-K (Filed: Feb 19, 2010) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2009 | Dec 31, 2008 | |
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $ 7,683 | 7,976 |
| Marketable securities | 831 | 289 |
| Receivables | 3,164 | 3,644 |
| Inventories | 1,413 | 1,765 |
| Deferred income taxes | 611 | 703 |
| Prepaid expenses | 256 | 320 |
| Total Current Assets | 13,958 | 14,697 |
| Property, plant and equipment | 5,055 | 5,405 |
| Goodwill | 5,218 | 4,827 |
| Other intangible assets | 2,865 | 1,151 |
| Deferred income taxes | 1,636 | 2,137 |
| Marketable securities | 1,369 | 188 |
| Other assets | 907 | 1,081 |
| Total Assets | 31,008 | 29,486 |
| LIABILITIES | ||
| Current Liabilities: | ||
| Short-term borrowings | 231 | 154 |
| Accounts payable | 1,711 | 1,535 |
| Accrued expenses | 2,785 | 2,974 |
| Deferred income | 237 | 277 |
| Accrued rebates and returns | 622 | 806 |
| U.S. and foreign income taxes payable | 175 | 347 |
| Dividends payable | 552 | 617 |
| Total Current Liabilities | 6,313 | 6,710 |
| Pension, postretirement and postemployment liabilities | 1,658 | 2,285 |
| Deferred income | 949 | 791 |
| U.S. and foreign income taxes payable | 751 | 466 |
| Other liabilities | 422 | 441 |
| Long-term debt | 6,130 | 6,585 |
| Total Liabilities | 16,223 | 17,278 |
| Commitments and contingencies (Note 24) | ||
| EQUITY | ||
| Bristol-Myers Squibb Company Shareholders' Equity: | ||
| Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 5,515 in 2009 and 5,668 in 2008, liquidation value of $50 per share | 0 | 0 |
| Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2009 and 2008 | 220 | 220 |
| Capital in excess of par value of stock | 3,768 | 2,757 |
| Accumulated other comprehensive loss | (2,541) | (2,719) |
| Retained earnings | 30,760 | 22,549 |
| Less cost of treasury stock - 491 million common shares in 2009 and 226 million in 2008 | (17,364) | (10,566) |
| Total Bristol-Myers Squibb Company Shareholders' Equity | 14,843 | 12,241 |
| Noncontrolling interest | (58) | (33) |
| Total Equity | 14,785 | 12,208 |
| Total Liabilities and Equity | 31,008 | 29,486 |
| External Links | |
| BRISTOL MYERS SQUIBB CO (BMY) Fiscal Year 2009 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |